urothelial carcinoma (advanced)

     

Select            
Trial Studied trt Control trt patientstagsROB Trial result

immune checkpoint inhibition

atezolizumab
IMvigor211 (IC2/3)      NCTatezolizumabchemotherapy2nd line, IC2/3 2nd line Risk of bias suggesting
IMVIGOR-130 (monotherapy)    NCTatezolizumabcontrolfirst line 1st line Risk of bias remark
IMvigor210 single-arm      NCTatezolizumabnil1st and 2nd line 1st line 2nd line Exploratory -
durvalumab
durvalumab phase 1/2 single-arm   durvalumabnil2nd line 2nd line Exploratory -
nivolumab
Checkmate 275 single-arm      NCTnivolumabnil2nd line 2nd line Exploratory -
pembrolizumab
KEYNOTE-052, 2017 single-arm      NCTpembrolizumab 1st line Risk of bias -
KEYNOTE-045, 2017    NCTpembrolizumabchemotherapy2nd line 2nd line Risk of bias suggesting
Keynote 361 monotherapy    NCTpembrolizumabchemotherapyfirst lineremark